Premium
Beyond ACE inhibition: new developments in drug therapy for hypertension
Author(s) -
Burrell Louise M,
Johnston Colin I
Publication year - 1995
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1995.tb126056.x
Subject(s) - renin–angiotensin system , pharmacology , endothelin receptor , vasopressin , nitric oxide , blockade , angiotensin ii , medicine , blood pressure , vasodilation , endogeny , receptor
The growing list of vasoactive substances known to be involved in blood pressure control provides new targets for antihypertensive drugs. Currently under development are alternative strategies for blockade of the renin‐angiotensin system (e.g., renin inhibition and angiotensin II receptor antagonism) that may have fewer side effects than angiotensin‐converting‐enzyme inhibition, and antagonists to other vasocontrictor peptides, such as endothelin and vasopressin. Novel strategies to enhance the effects of endogenous vasodilators, such as natriuretic peptides and nitric oxide, are also being explored.